Alpha-9 Oncology is a clinical stage, radiopharmaceutical company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer. Applying proprietary technologies and deep-foundational expertise, Alpha-9 is on the forefront of engineering bespoke radiopharmaceuticals that are optimized to selectively deliver radiation to tumor sites while minimizing off-target effects. Alpha-9 is advancing a robust pipeline of novel radiopharmaceuticals with a systematic approach to molecule design that offers broad potential for expansion into several validated oncology targets. Alpha-9 was founded by researchers from the University of British Columbia and BC Cancer, with the goal of improving the lives of patients affected by metastatic cancers.
External link for Alpha-9 Oncology
Boston, Massachusetts, US
Vancouver, BC, CA
Excited to announce another milestone - great work team!
Today Alpha-9 Oncology Inc. announces the closing of oversubscribed $175 million Series C financing to advance its diverse clinical pipeline of #radiopharmaceuticals for effective #cancer treatments. The Financing was led by Lightspeed Venture Partners and Ascenta Capital. Learn more: https://lnkd.in/gG3qqDgg
Today Alpha-9 Oncology Inc. announces the closing of oversubscribed $175 million Series C financing to advance its diverse clinical pipeline of #radiopharmaceuticals for effective #cancer treatments. The Financing was led by Lightspeed Venture Partners and Ascenta Capital. Learn more: https://lnkd.in/gG3qqDgg
We’re thrilled to welcome industry veterans Jean-Jacques Bienaimé and Steven Stein, M.D., to our board of directors. Their extensive operational and clinical expertise will be instrumental in advancing our programs through clinical stages, significantly enhancing treatment options for those living with cancer. https://lnkd.in/eGvxh963
We’re pleased to announce we have dosed the first participant in our Phase 1 clinical trial evaluating 68Ga-A9-3202, a melanocortin 1 receptor (MC1R) targeting agent for the imaging of locally advanced or metastatic #melanoma. This is an important milestone for our company as we continue to advance our portfolio of therapeutic molecules into the clinic. Read more: https://lnkd.in/df9_Y-F4
Today we announced a long-term supply agreement with ITM Isotope Technologies Munich SE that provides Alpha-9 with ITM’s non-carrier-added Lutetium-177 (n.c.a. 177Lu) for Alpha-9’s Lutetium-based candidates for the treatment of cancer. Read more: https://lnkd.in/ektbV_pG
Today we announced a long-term supply agreement with NorthStar Medical Radioisotopes, LLC, providing Alpha-9 with NorthStar’s high purity non-carrier added (n.c.a.) Ac-225 to be used in our targeted #radiopharmaceutical programs for the treatment of solid and liquid tumors. Read more: https://lnkd.in/enZfyRZP